P J Gow
Overview
Explore the profile of P J Gow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Batt N, Rodrigues B, Bloom S, Sawhney R, George E, Hodge A, et al.
J Gastroenterol Hepatol
. 2024 Feb;
39(6):1048-1056.
PMID: 38369382
Background And Aim: The rising incidence of hepatocellular carcinoma (HCC) in Australia is related to increasing rates of metabolic-associated fatty liver disease (MAFLD). This study aimed to prospectively characterize the...
2.
Sood S, Haifer C, Yu L, Pavlovic J, Gow P, Jones R, et al.
Transpl Infect Dis
. 2018 May;
20(5):e12934.
PMID: 29809312
Introduction: Although antiviral prophylaxis is effective in preventing early cytomegalovirus (CMV) reactivation following liver transplantation (OLT), it predisposes patients to late CMV after prophylaxis has ceased. QuantiFERON-CMV (QFN-CMV, Qiagen, The...
3.
Sinclair M, Gow P, Grossmann M, Angus P
Aliment Pharmacol Ther
. 2016 Feb;
43(7):765-77.
PMID: 26847265
Background: Sarcopenia (loss of muscle mass) is common in cirrhosis and is associated with poor outcomes. Current teaching recommends the use of protein supplementation and exercise, however, this fails to...
4.
Page M, Ekinci E, Jones R, Angus P, Gow P, OBrien R
Intern Med J
. 2014 Jun;
44(6):601-4.
PMID: 24946816
Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective....
5.
Mackay A, Angus P, Gow P
Transplant Proc
. 2011 Dec;
43(10):3802-6.
PMID: 22172850
Background: It has become common practice to withdraw or reduce calcineurin inhibitors (CNI) in patients with renal dysfunction after liver transplantation; however, little is known about the long-term outcome of...
6.
Rode A, Jones R, Angus P, Brown D, Gow P
Intern Med J
. 2011 Jun;
41(6):509-10.
PMID: 21707900
No abstract available.
7.
Hollis-Moffatt J, Merriman M, Rodger R, Rowley K, Chapman P, Dalbeth N, et al.
Ann Rheum Dis
. 2008 Jul;
68(8):1340-4.
PMID: 18647855
Objective: The rare allele of a non-synonymous interleukin 23 receptor (IL23R) single nucleotide polymorphism (SNP) rs11209026 (p.Arg381Gln) confers strong protection against Crohn disease (CD) and psoriasis. Other IL23R variants also...
8.
McKinney C, Merriman M, Chapman P, Gow P, Harrison A, Highton J, et al.
Ann Rheum Dis
. 2007 Jul;
67(3):409-13.
PMID: 17604289
Objective: There is increasing evidence that gene copy-number variation influences phenotypic variation. Chemokine ligand 3-like 1 (CCL3L1) is encoded by a variable copy-number gene, and binds to several pro-inflammatory cytokine...
9.
Sutedja D, Gow P, Hubscher S, Elias E
Transplant Proc
. 2004 Nov;
36(8):2334-7.
PMID: 15561241
Introduction: Because of the tendency for preexisting diseases to recur following liver transplantation, studying the course of patients who were transplanted for their cryptogenic cirrhosis may reveal features of the...
10.
Wali M, Harrison R, Gow P, Mutimer D
Gut
. 2002 Jul;
51(2):248-52.
PMID: 12117889
Background And Aim: Cirrhosis with liver failure due to hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT). Reinfection of the transplanted liver by HCV...